Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pituitary
Published in: Pituitary 1/2007

01-03-2007 | Case Report

Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists

Authors: Lisa M. Neff, Michelle Weil, Alan Cole, Thomas R. Hedges, William Shucart, Donald Lawrence, Jay-Jiguang Zhu, Arthur S. Tischler, Ronald M. Lechan

Published in: Pituitary | Issue 1/2007

Login to get access

Abstract

Prolactinomas are common tumors of the anterior pituitary gland. While conventional therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are usually effective in controlling tumor growth, some patients develop treatment-resistant tumors. In this report, we describe a patient with an invasive prolactinoma resistant to conventional therapy that responded to the administration of the alkylating agent, temozolomide.
Literature
1.
Gillam M, Molitch M, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocrine Rev 27:485–534CrossRef
2.
3.
Saeger W, Farrell WE, Horvath E, Lloyd RV, Kovacs K, Watson RE Jr, Lindell EP (2004) Proloctin secreting adenoma. In: DeLellis R, Lloyd R, Heitz P (eds) WHO classification of tumours, pathology & genetics, tumours of endocrine organs. IARC Press, Lyon, pp 20–23
4.
Riss D, Jin L, Qian X, Bayliss J, Scheithauer B, Young WJ, Vidal S, Kovacs K, Raz A, Lloyd R (2003) Differential expression of galectin-3 in pituitary tumors. Cancer Res 63:2251–2255PubMed
5.
Zhu Y, Shahinian H, Bonert V, Lim S, Heaney A (2004) OR 43–5 Temodar: novel treatment for pituitary carcinoma. In The Endocrine Society Annual Meeting
6.
Lim S, Shahinian H, Maya M, Yong W, Heaney A (2006) Temodar: novel treatment for pituitary carcinoma. Lancet Oncol 7:518–520PubMedCrossRef
7.
Tsagarakis S, Grossman A, Plowman P, Jones A, Touzel R, Rees L, Wass J, Besser G (1991) Megavoltage pituitary irradiation in the management of prolactinomas: long-term follow-up. Clin Endocrinol 34:399–406
8.
Tsang R, Brierley J, Panzarella T, Gospodarowicz M, Sutcliffe S, Simpson W (1996) Role of radiation therapy in clinical hormonally-active pituitary adenomas. Radiother Oncol 41:45–53PubMedCrossRef
9.
Brada M, Ajithkumar T, Minniti G (2004) Radiosurgery for pituitary adenomas. Clin Endocrinol 61:531–543CrossRef
10.
Garcia M, Kapcala L (1995) Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy. J Endocrinol Invest 18:450–455PubMed
11.
12.
13.
Karumakaran S, Page R, Wass J (2001) The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol 54:295–300CrossRef
14.
Kaptain G, Simmons N, Alden T, Lopes M, Vance M, Laws E (1999) Estrogen receptors in prolactinomas: a clinico-pathological study. Pituitary 1:91–98PubMedCrossRef
15.
Lamberts S, Verleun T, Hofland L, Oosterom R (1986) Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. J Clin Endocrinol Metab 63:1342–1347PubMedCrossRef
16.
Volker W, Gehring W, Berning R, Schmidt R, Schneider J, von zur Muhlen A (1982) Impaired pituitary response to bromocriptine suppression: reversal after bromocriptine plus tamoxifen. Acta Endocrinol 101:491–500PubMed
17.
Lamberts S, Verleun T, Oosterom R (1982) Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas. Neuroendocrinol 34:339–342
18.
Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom H, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy P, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A (2004) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101–2109CrossRef
19.
Thurlimann B, Keshaviah A, Coates A, Mouridsen H, Mauriac L, Forbes J, Paridaens R, Castiglione-Gertsch M, Gelber R, Rabaglio M, Smith I, Wardly A, Price K, Goldhirsch A (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New Engl J Med 353:2747–2757PubMedCrossRef
20.
Gilliam M, Middler S, Freed D, Molitch M (2002) The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 87:4447–4451CrossRef
21.
22.
Lamberts S, Zweens M, Klijn J, van Vroonhoven C, Stefanko S, Del Pozo E (1986) The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201–995 in patients with prolactinomas and acromegaly. Clin Endocrinol 25:201–212
23.
Jaquet P, Ouafik L, Saveanu A, Gunz G, Fina F, Dufour H, Culler M, Moreau J (1999) Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab 84:3268–3276PubMedCrossRef
24.
Shimon I, Yan X, Taylor J, Weiss M, Culler M, Melmed S (1997) Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 100:2386–2392
25.
Hofland L, van der Hoek J, van Koetsveld P, de Herder W, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely A, Beckers A, Lamberts S (2004) The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 89:1577–1585PubMedCrossRef
26.
Grottoli S, Gasco V, Broglio F, Baldelli R, Ragazzoni F, Gallenca F, Mainolfi A, Prodam F, Muccioli G, Ghigo E (2006) Cortistatin-17 and somatostatin-14 display the same effects on growth hormone, prolactin, and insulin secretion in patients with acromegaly or prolactinoma. J Clin Endocrinol Metab 91:1595–1599PubMedCrossRef
27.
Rocheville M, Lange D, Kumar U, Patel S, Patel R, Patel Y (2000) Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288:154–157PubMedCrossRef
28.
Seveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor J, Culler M, Enjalbert A, Jaquet P (2002) Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 87:5545–5552CrossRef
29.
Kaltsas G, Mukherjee J, Plowman P, Monson J, Grossman A, Besser G (1998) The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab 83:4233–4238PubMedCrossRef
30.
Hurel S, Harris P, McNicol A, Foster S, Kelly W, Baylis P (1997) Metastatic prolactinoma: effect of octreotide, cabergoline, carboplatin, and etoposide: immunocytochemical analysis of proto-oncogene expression. J Clin Endocrinol Metab 82:2962–2965PubMedCrossRef
31.
Kulke M, Stuart K, Enzinger P, Ryan D, Clark J, Muzikansky A, Vincitore M, Michelini A, Fuchs C (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401–406PubMedCrossRef
32.
Bafaloukos D, Tsoutsos D, Kalofonos H, Chalkidou S, Panagiotou P, Linardou E, Briassoulis E, Efstathiou E, Polyzos A, Fountzilas G, Christodoulou C, Kouroussis C, Iconomou T, Gogas H (2005) Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 16:950–957PubMedCrossRef
33.
Nagasubramanian R, Dolan M (2003) Temozolomide: realizing the promise and potential. Curr Opin Oncol 15:412–418PubMedCrossRef
34.
Hegi M, Diserens A, Godard S, Dietrich P, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871–1874PubMedCrossRef
35.
Roos W, Batista L, Naumann S, Wick W, Weller M, Menck C, Kaina B (2006) Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene (advance online publication). doi:10.1038/sj.onc.1209785
36.
Esteller M, Hamilton S, Burger P, Baylin S, Herman J (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793–797PubMed
37.
Hegi M, Diserens A, Gorlia T, Hamou M, de Tribolet N, Weller M, Kros J, Hainfellner J, Mason W, Mariani L, Bromberg J, Hau P, Mirimanoff R, Cairncross J, Janzer R, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003PubMedCrossRef
Metadata
Title
Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists
Authors
Lisa M. Neff
Michelle Weil
Alan Cole
Thomas R. Hedges
William Shucart
Donald Lawrence
Jay-Jiguang Zhu
Arthur S. Tischler
Ronald M. Lechan
Publication date
01-03-2007
Published in
Pituitary / Issue 1/2007
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-007-0014-1

Other articles of this Issue 1/2007

Pituitary 1/2007 Go to the issue

OriginalPaper

Progressive improvement of impaired visual acuity during the first year after transsphenoidal surgery for non-functioning pituitary macroadenoma

Erratum

Efficacy and safety of CyberKnife radiosurgery for acromegaly

OriginalPaper

Treatment of acromegaly: is there still a place for radiotherapy?

OriginalPaper

Gene expression profiling in human null cell pituitary adenoma tissue

OriginalPaper

Efficacy and safety of CyberKnife radiosurgery for acromegaly

Case Report

Clinical presentation and response to therapy in patients with massive prolactin hypersecretion
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits